Sai Life Sciences Limited, a leading Contract Research, Development, and Manufacturing Organisation (CRDMO), has successfully completed Phase II of its Production Block 11 (PB-11) at its flagship API manufacturing facility in Bidar, Karnataka (Unit IV). With this new addition of approximately 91 KL in Phase II — following 110 KL added during Phase I in December 2024 — PB-11 now contributes a total of ~200 KL, making it the largest single reactor volume block at the site. This milestone brings the total installed reactor capacity at the Bidar site to approximately 700 KL, significantly enhancing the company’s ability to support late-stage and commercial-scale manufacturing programs.
Commenting on the development, Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences, said“Our goal is to be a reliable partner to our clients as they scale up their programs. This expansion is not just about capacity — it’s about demonstrating our ability to grow alongside our partners, handle increasing complexity, and deliver with confidence. By reinforcing our infrastructure at Bidar, we’re empowering our customers to speed up development, reduce supply chain risks, and bring new therapies to market faster.”
PB-11 is a multi-purpose block, built to accommodate large-scale commercial API production. The facility is engineered to meet the demanding requirements of global regulatory markets, including the US, Europe, and Japan.
The Bidar site (Unit IV) stands as the company’s flagship manufacturing hub, equipped with state-of-the-art infrastructure and extensive production capabilities. The facility houses 12 production blocks with a combined reactor volume of approximately 700 KL, enabling large-scale operations to meet diverse manufacturing needs. It is designed to support high-performance production while ensuring flexibility across a wide portfolio of pharmaceutical products.
In addition to scale, the site offers specialized strengths that set it apart. It features dedicated High Potency API (HPAPI) production areas, advanced quality control laboratories for rigorous testing, and facilities tailored for complex processes such as lyophilization, cryogenic and high-pressure reactions, and commercial-scale chromatography. These capabilities make the Bidar site a cornerstone in delivering high-quality, reliable, and specialized pharmaceutical solutions.
The facility has received approvals from leading regulatory bodies such as the USFDA, PMDA (Japan), and CDSCO (India). As of March 2025, Sai Life Sciences has completed over 75 customer audits across its manufacturing units over the past three years — a strong reflection of its commitment to quality, safety, and compliance.
Sai Life Sciences is a globally recognized CRDMO, working with over 300 pharmaceutical and biotech innovators worldwide. With over 26 years of experience, the company supports the entire lifecycle of small molecule programs — from discovery and development to commercial manufacturing. Operating with a team of more than 3,400 professionals, Sai Life Sciences has established world-class facilities across India, combining deep scientific expertise with robust compliance standards to deliver results at every stage of the development journey.
